New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
10:04 EDTHTGC, CLSNCelsion closes second $5M tranche under Hercules Loan Facility Agreement
Celsion (CLSN) announced that it has closed the second $5M tranche under its $20M Loan and Security Agreement dated as of November 25, 2013 with Hercules Technology (HTGC). The proceeds will be used to fund the $3.4M upfront cash payment associated with Celsion's acquisition of EGEN, which was announced separately today, as well as Celsion's transaction costs associated with the EGEN transaction. Upon the closing of this second tranche, Celsion has drawn down a total of $10M under the November 25, 2013 agreement with Hercules. The funding is in the form of secured indebtedness bearing interest at a floating prime-based variable rate. In conjunction with the November 2013 loan agreement, Celsion issued Hercules a warrant exercisable for a total of 194,986 shares of Celsion's common stock at a per share exercise price of $3.59, with 50% immediately exercisable and the remaining 50% exercisable upon Hercules' funding of this $5M draw-down. The Hercules Warrant will expire November 25, 2018.
News For CLSN;HTGC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
07:06 EDTCLSNAmerican Society of Clinical Oncology to hold annual meeting
Subscribe for More Information
May 28, 2015
08:48 EDTCLSNCelsion announces $8M at-the-market registered direct offering
Celsion has received commitments from two institutional healthcare investors to purchase an aggregate of approximately $8M of the company's common stock in an at-the-market registered direct offering and a concurrent private placement of warrants to purchase common stock. The company has agreed to sell an aggregate of 3M shares of its common stock at a per share price of $2.675 in a registered direct offering. Additionally, in a concurrent private placement, the company agreed to issue to the investors warrants to purchase, for each share of common stock purchased in the registered direct offering, 0.65 share of common stock for a total of 1.95M shares of common stock. The warrants have an exercise price of $2.60 per share and will expire five years from the date of issuance. The closing of the registered direct offering and the concurrent private placement is expected on or about June 1. The estimated net proceeds to the company in the registered direct offering are expected to be approximately $7.3M. The company intends to use the net proceeds for general corporate purposes.
08:47 EDTCLSNCelsion announces $8M at-the-market registered direct offering
Subscribe for More Information
May 26, 2015
09:58 EDTHTGCOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: L Brands (LB) upgraded to Conviction Buy from Buy at Goldman... Dollar General (DG) upgraded to Conviction Buy from Buy at Goldman... Accenture (ACN) upgraded to Outperform from Market Perform at Cowen... Expedia (EXPE) upgraded to Outperform from Market Perform at JMP Securities... The Fresh Market (TFM) upgraded to Neutral from Underperform at Longbow... Marvell (MRVL) upgraded to Overweight from Equal Weight at Morgan Stanley... Health Care REIT (HCN) upgraded to Buy from Neutral at Mizuho... Gold Fields (GFI) upgraded to Buy from Hold at HSBC... eBay (EBAY) upgraded to Buy from Hold at Axiom... CNOOC (CEO) upgraded to Neutral from Underweight at JPMorgan... Quintiles (Q) upgraded to Buy from Neutral at SunTrust... DCT Industrial (DCT) upgraded to Neutral from Underperform at Credit Suisse... Pebblebrook Hotel (PEB) upgraded to Outperform from Neutral at Credit Suisse... Fortinet (FTNT) upgraded to Buy from Hold at Needham... BB&T (BBT) upgraded to Buy from Neutral at Guggenheim... Hercules Technology (HTGC) upgraded to Outperform from Neutral at Macquarie... InterXion (INXN) upgraded to Buy from Hold at Stifel.
07:00 EDTHTGCHercules Technology upgraded to Outperform from Neutral at Macquarie
Macquarie upgraded Hercules Technology to Outperform with a $14 price target following last week's investor meetings with CEO Manuel Henriquez. The firm's analyst came away with increased confidence in Hercules' dividend coverage and the prospects for moderating competition following several acquisitions.
May 21, 2015
08:10 EDTCLSNCelsion's TheraSilence RNA program shows positive preclinical data
Subscribe for More Information
May 15, 2015
08:03 EDTCLSNCelsion announces preclinical data confirming delivery of RNA to lung cells
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use